This HTML5 document contains 147 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n12http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q33859790
rdf:type
wikibase:Item
schema:description
article científic 2016 թվականի հուլիսին հրատարակված գիտական հոդված mokslinis straipsnis 2016年論文 2016年论文 article scientific سائنسی مضمون artigo científico 2016年論文 мақолаи илмӣ teaduslik artikkel tieteellinen artikkeli 2016年论文 scienca artikolo artículo científico publicado en 2016 artykuł naukowy artikull shkencor wetenschappelijk artikel επιστημονικό άρθρο 2016年论文 vetenskaplig artikel บทความทางวิทยาศาสตร์ научни чланак научная статья artículu científicu espublizáu en 2016 articolo scientifico artigo científico (publicado na 2016) bilimsel makale wissenschaftlicher Artikel 2016年論文 2016년 논문 2016年の論文 مقالة علمية videnskabelig artikel (udgivet 2016) article scientifique (publié 2016) научни чланак مقالهٔ علمی 2016年论文 artigo científico (publicado na 2016) artikulong pang-agham מאמר מדעי vitenskapelig artikkel 2016年论文 vedecký článok tudományos cikk 2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած ২০১৬-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2016年論文 2016年论文 vědecký článek naučni članak სამეცნიერო სტატია мақолаи илмӣ articol științific 2016年論文 bài báo khoa học 2016 nî lūn-bûn vitskapeleg artikkel наукова стаття, опублікована в липні 2016 научна статия scientific article
p:P577
wds:Q33859790-6B04DD6B-62E7-49A1-AEB7-BB5E718504B0
wdt:P577
2016-07-27T00:00:00Z
p:P2860
wds:Q33859790-127B8FE5-D7FC-4D8F-8ADC-A5AD413BF124 wds:Q33859790-139F1B93-294B-4CA3-B77B-ED109E9A51DC wds:Q33859790-33FB4D00-1655-4031-9508-28805ECA5F43 wds:Q33859790-03FB5D7A-762E-415D-B142-EF62C48925C7 wds:Q33859790-0A8BFF4D-6542-487B-90DD-8632457F8932 wds:Q33859790-0B0264A3-C556-46EC-A251-D29591BB7392 wds:Q33859790-00BEA22B-8D11-46ED-B73B-BB00E7816C39 wds:Q33859790-F36C11F2-71DF-41D9-B85A-A0EC1E1EF36A wds:Q33859790-FBD1D7D1-22E7-4BD8-A432-D335940C43EC wds:Q33859790-EB08CA63-8171-4F15-B3DB-360D2EEB9C32 wds:Q33859790-EDDA9266-8858-4F4F-BE4F-1FFB209DFFB0 wds:Q33859790-B7FCF867-3D3F-4C41-897F-7C5F1D1A55DF wds:Q33859790-C6ED14F9-FB38-4DEA-9BD2-1A80A2ADDDD0 wds:Q33859790-A7385AC0-08DA-47EE-A817-B7AC3661586D wds:Q33859790-B2C12DE4-709D-40A6-BAEF-A8D5EAC5330D wds:Q33859790-B77D06C9-8698-4E93-AEF2-4350B424AE00 wds:Q33859790-795FC54A-5FA3-4E95-AF8F-B2C25CC3DFA8 wds:Q33859790-8C3F8B38-8D3F-4DEC-9DAF-94E32654E63F wds:Q33859790-A1A29800-C67F-4276-8EA9-E747C4387BAF wds:Q33859790-794B1DCC-E6DC-43F3-86FE-88327E7FF83A wds:Q33859790-3E6CD315-4349-45AD-BC0A-7BBA81D74723 wds:Q33859790-628DEB4B-7366-4F00-97E3-A2C60D2F58B9
wdt:P2860
wd:Q33566222 wd:Q87665068 wd:Q27861047 wd:Q38386664 wd:Q33866095 wd:Q46807926 wd:Q37696468 wd:Q63199181 wd:Q38554663 wd:Q30434661 wd:Q82032106 wd:Q38418806 wd:Q46879501 wd:Q35563197 wd:Q30436932 wd:Q35737223 wd:Q38302729 wd:Q34973414 wd:Q26851916 wd:Q41233511 wd:Q34176394 wd:Q36822179
p:P2093
wds:Q33859790-50EADB8B-3014-4EC7-9AEB-D204CAF43B27
wdt:P2093
Mahesh Iddawela
rdfs:label
Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries. Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries. Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries.
skos:prefLabel
Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries. Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries. Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries.
schema:name
Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries. Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries. Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries.
p:P50
wds:Q33859790-F0B739D6-CD5F-4F33-B1BA-F47351E69715
wdt:P50
wd:Q42397411
p:P1476
wds:Q33859790-D8EF6D4F-8F7B-4C8F-897F-23A98EE918BC
wdt:P1476
Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries
p:P304
wds:Q33859790-106D7156-62B7-4022-8BE1-A978B24F773A
wdt:P304
93-97
p:P31
wds:Q33859790-0ED35605-B41C-456F-BD72-BEC2A09C902C
wdt:P31
wd:Q13442814
p:P921
wds:Q33859790-ABE979EF-108B-481C-B30B-8626AE598CFA wds:Q33859790-F1615688-8028-4D5C-A9D5-D1179EC2A54B
wdt:P921
wd:Q160105 wd:Q413299
p:P698
wds:Q33859790-03BE8105-AAAB-498E-8E8B-EFDD847163DA
wdtn:P698
n11:28717748
wdt:P698
28717748
p:P1433
wds:Q33859790-D13593CC-83FF-4038-BCC7-18F77948D77A
wdt:P1433
wd:Q27727124
p:P433
wds:Q33859790-A333B9C9-CF49-4F15-8313-58826E9904A7
p:P478
wds:Q33859790-72D4BD1D-FDD8-4D02-A583-7606B6A621EE
wdt:P433
2
wdt:P478
3
p:P356
wds:Q33859790-6658115F-EEFA-426D-A2C6-A99F0DD1ED7F
wdtn:P356
n12:JGO.2016.004895
wdt:P356
10.1200/JGO.2016.004895
p:P8608
wds:Q33859790-F72C8EBA-21EB-4FA2-90C8-E33086CEB235
wdt:P8608
release_bdff7v3gifgzvlfl67l67glpxq
p:P932
wds:Q33859790-67AE26DB-AFD2-41A6-9726-4ACDFA371233
wdt:P932
5493276